Rare Diseases: Innovation, Investment, and Unmet Needs – Strategic Intelligence
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Rare disease is a large, structurally underserved market.
Development activity is heavily weighted to oncology, but oncology is also the least mature part of the pipeline.
Dealmaking in rare disease has accelerated sharply, with 2026 already the biggest year on record for M&As.
Orphan drug designations keep climbing, but regulatory approval does not guarantee patients can actually get the drug.
Scope
This report talks about the rare disease landscape, including where drug dveelopment is concentrated across therapy areas, indications, and modalities. Also, the most active companies in this field are highlighted and how they are building through M&As and licensing agreements, all while the regulatory and access environment is continuously evolving.
Reasons to Buy
This report talks about the rare disease landscape, including where drug dveelopment is concentrated across therapy areas, indications, and modalities. Also, the most active companies in this field are highlighted and how they are building through M&As and licensing agreements, all while the regulatory and access environment is continuously evolving.
Roche
Pfizer
AstraZeneca
Novartis
BMS
GSK
IQVIA
Lonza Group
Catalent
Thermo Fisher
Sanofi,BeiGene
Regeneron
CSL
Argenx
Abzena
Curebase
Raremark
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745